SYSTEMATIC REVIEW article
Front. Med.
Sec. Gastroenterology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1580203
This article is part of the Research TopicThe Gut Microbiome's Role in Gastric Cancer: Mechanisms and TherapiesView all 6 articles
Comparison of tegoprazan based-and proton pump inhibitor based-regimens for Helicobacter pylori eradication: A meta-analysis and system review
Provisionally accepted
- 1Changsha Fourth Hospital, Changsha, Hunan Province, China
- 2Changsha Hospital of Traditional Chinese Medicine, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background and aims: Tegoprazan (TEG) is a new potassium-competitive acid blocker that provides a long-lasting acid-suppressing effect. The role of TEGbased Helicobacter pylori (H. pylori) eradication regimens compared with proton pump inhibitor (PPI)-based regimens requires study.We conducted a comprehensive search across multiple databases. Studies comparing H. pylori eradication rates, adverse events (AEs), and compliance between TEG-based and PPI-based regimens were included. Statistical analyses were performed using RevMan 5.4.Results: Eight studies with 4640 patients were included. Based on intention-to-treat (ITT) analyses, the overall eradication rate (78.6% vs. 76.6%; odds ratio [OR] = 1.08, 95% CI: 0.93-1.24; p = 0.31, I² = 0%) and compliance (97.8% vs. 97.8%; OR = 1.16, 95% CI: 0.54-2.50; p = 0.33, I² = 13%) were comparable between the TEG and PPI groups. The AE rate of TEG-based regimens was significantly lower than that of PPIbased regimens (30.8% vs. 34.9%; OR = 0.88; 95% CI: 0.78-1.00; p = 0.04, I² = 67%), though this difference was not significant in RCTs. Subgroup analyses showed higher eradication rates in studies conducted in China, those with treatment durations of 10 or 14 days, and those using dual or bismuth quadruple regimens. However, treatment regimens did not significantly influence eradication rates within any subgroup.TEG-based H. pylori eradication treatment demonstrated eradication rates, compliance, and safety comparable to those of PPI-based regimens.
Keywords: Helicobacter pylori, Tegoprazan, proton pump inhibitor, eradication, Compliance, adverse events
Received: 21 Feb 2025; Accepted: 31 Mar 2025.
Copyright: © 2025 Zhang, Li, Li, Deng, Xu, Chen and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xin Zhang, Changsha Fourth Hospital, Changsha, 410006, Hunan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.